BI
Swedish Orphan Biovitrum AB (publ)
BIOVF · OTC
$48.13 +0.00% (+$0.00)
1M -0.06%
Market Cap 160.3B kr
P/E Ratio 114.74x
Div. Yield -
ROE 3.58%
Bulios Fair Price
$54.79
13.8% upside
Current Price
$48.13
Undervalued Fair Value Overvalued
According to Bulios Fair Price, BIOVF is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Moderate
6/9Valuation
41 /100
Fair P/E 114.74x
EV/EBITDA 13.88x
P/FCF 22.17x
Growth
64 /100
Stable EPS growth 45.32%
Rev. growth 14.45%
Book val. growth 12.36%
Profitability
87 /100
Strong Gross margin 51.63%
Net margin 4.57%
FCF margin 23.67%
Quality
42 /100
Average ROIC 14.05%
ROE 3.58%
Asset turnover 0.37x
Debt
73 /100
Low Debt/Equity 0.42x
Current ratio 0.88x
Net debt/EBITDA 1.30x
Stability
54 /100
Moderate Beta 0.29x
Rev. volatility 5.47%
Profitable years 6
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about BIOVF
Online
Sector
Healthcare
Industry
Medical - Pharmaceuticals
CEO
Guido Oelkers
Employees
1,888
Headquarters
Stockholm
Upcoming events
27 OCT
Earnings
Upcoming earnings report